Sema4 announced that R. Martin Chavez, a prominent Wall Street and technology executive, has joined its Board of Directors.
Sema4 announced that it has been named a 2020 Cool Vendor in Healthcare Technology by Gartner Inc., the world’s leading research and advisory company.
Sema4 announced that it is now performing rapid molecular testing for the detection of SARS-CoV-2, the coronavirus responsible for COVID-19.
Sema4 announced the appointment of Rachel Sherman, MD, MPH, to its Board of Directors. Dr. Sherman is the former Principal Deputy Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA).
Clinical OMICs published an article covering Sema4’s strategic alliance with VieCure. The piece covers how the collaboration between the two companies is accelerating precision oncology care.